Authorities in China have released more information about the accusations against GlaxoSmithKline relating to bribery and corruption in China.

The Chinese government announced more tails about the allegations against the company saying that its unit was involved in the scandal in the country. The company said that Hervé Gisserot, who is one of the leading executives in Europe, will succeed Mark Reilly as the head of its operations in China. Mr. Reilly has left the country for the UK after the company's headquarters were raided by the authorities in China.

Police in China had accused GSK of bribing officials and doctors on Monday for increasing sales and the prices of medicines in the Chinese markets. It has been alleged that the company paid up to 3 billion yuan or $489 million to 700 travel agencies and consultancies for facilitating the transfer of bribes. Chinese authorities are investigating investigations of a wrong practices and crackdown on bribery in the pharmaceutical industry in China.

Britain's biggest drug-maker has shown that it is taking the situation seriously by sending top three officials to the country, which is an important and fast growing market for the industry. GSK also said that it is concerned over the allegations against it operations in China. Chief Executive Andrew Witty has sent Abbas Hussain, GSK President Emerging Markets as well as the group's global head of internal audit and a senior legal official to China for controlling the crisis.